LeMaitre Vascular, Inc. reported strong first-quarter results with 10% organic revenue growth, gross margins of 72.1%, and adjusted earnings per share of $0.68, exceeding the consensus estimate of $0.66. Despite these solid fundamentals, the stock fell after the earnings release as investors took profits in one of the medical device sector's strongest performers. Prior to reporting first-quarter results on May 5, 2026, LMAT shares had appreciated approximately 38% year-to-date. Conestoga Capital Advisors, which highlighted the company in its second-quarter 2026 investor letter, continues to believe LeMaitre Vascular is well positioned for attractive revenue and earnings growth, supported by its differentiated vascular product portfolio and consistent execution.
LeMaitre Vascular IncStock fell despite strong earnings as investors took profits after a 38% YTD run.
